FDA Assessment Reinforces the Importance of Patient-Focused Evidence
New findings highlight the growing role of patient experience data and fit-for-purpose clinical outcome assessments in regulatory decision-making
Learn More About Patient-Centered Outcomes ResearchThe FDA recently published its Assessment of the Use of Patient Experience Data in Regulatory Decision-Making, offering a closer look at how patient-focused evidence is being incorporated into drug development and regulatory review.
One finding stands out: 73% of original New Molecular Entity (NME) NDA applications contained patient experience data, and approximately 40% of approved labels referenced patient-focused evidence.
These findings reinforce the importance of building a thoughtful patient-focused evidence strategy early and carrying it through the product development lifecycle.
To learn more about how our patient-centered outcomes research team at Modus, a Division of THREAD, supports these new findings, visit: https://www.threadresearch.com/solutions/pcor
Rare Trials Summit
Join Erica Spies, MS, PhD, Executive Scientific Director, Research and Strategy at Modus Outcomes, a Division of THREAD, as she moderates a live discussion exploring what rare disease therapies need to prove and how regulators, investors, payers, and patients each shape which therapies move forward.
Who Really Decides Which Rare Disease Therapies Survive: Regulators, Investors, Payers, or Patients? Wednesday, September 16 | 9:45–10:30 AM ET Track 4 | InterContinental Boston